CYBB and Parkinson disease: In the present study, using Nox2-specific inhibitor, gp91 ds, we are able to quantify Nox2-dependent ROS generation in response to rotenone treatment and characterize the novel mechanisms by which Nox2-dependent oxidative stress leads to the pathogenesis of sporadic forms of PD.